AKT1 and nonpapillary renal cell carcinoma: Furthermore, the compound LY294002, which inhibits the AKT/mTOR signaling pathway, was able to reverse the enhanced proliferation, migration, and invasion capabilities produced by the suppression of TRIM26 in ccRCC cells.